organization · Reporting owner
MLCP GLL Funding LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ensysce Biosciences, Inc.LACQ · Entity 8108 | 10% owner | June 30, 2021 | July 01, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ensysce Biosciences, Inc.
Report date June 30, 2021 · Filed July 01, 2021
Jointly reported with Silvers Daniel B., Matthews Lane Capital Partners LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2026-06-30 | IndirectMLCP GLL Funding LLC | 1,637,390 |
Reported balance
After 2021-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-30 · Grant · Acquired 1,637,390 · Balance 1,637,390 F1: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Silvers served as the Issuer's Chief Executive Officer and Director until the closing of the business combination. F2: Matthews Lane Capital Partners LLC, a sponsor of the Issuer, is the manager of MLCP GLL Funding LLC, the record holder of the warrants. Mr. Silvers is the managing member of Matthews Lane Capital Partners LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2026-06-30 | IndirectMLCP GLL Funding LLC | 2,004,497 |
Reported balance
After 2021-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-30 · Grant · Acquired 367,107 · Balance 2,004,497 F3: Reflects warrants acquired at a price of $1.00 per warrant upon the conversion of promissory notes of the Issuer reflecting amounts loaned to the Issuer pursuant to the Issuer's expense advancement agreement, which were convertible into warrants at the holder's option. The warrants are on the same terms as the warrants described in note (1) above. F2: Matthews Lane Capital Partners LLC, a sponsor of the Issuer, is the manager of MLCP GLL Funding LLC, the record holder of the warrants. Mr. Silvers is the managing member of Matthews Lane Capital Partners LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2026-06-30 | IndirectMLCP GLL Funding LLC | 1,754,497 |
Reported balance
After 2021-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-06-30 · Disposition to issuer · Disposed 250,000 · Balance 1,754,497 F4: Reflects warrants surrendered to the Issuer in connection with the Issuer's business combination pursuant to a warrant surrender agreement, for no consideration. F2: Matthews Lane Capital Partners LLC, a sponsor of the Issuer, is the manager of MLCP GLL Funding LLC, the record holder of the warrants. Mr. Silvers is the managing member of Matthews Lane Capital Partners LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Silvers served as the Issuer's Chief Executive Officer and Director until the closing of the business combination.
F2: Matthews Lane Capital Partners LLC, a sponsor of the Issuer, is the manager of MLCP GLL Funding LLC, the record holder of the warrants. Mr. Silvers is the managing member of Matthews Lane Capital Partners LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein.
F3: Reflects warrants acquired at a price of $1.00 per warrant upon the conversion of promissory notes of the Issuer reflecting amounts loaned to the Issuer pursuant to the Issuer's expense advancement agreement, which were convertible into warrants at the holder's option. The warrants are on the same terms as the warrants described in note (1) above.
F4: Reflects warrants surrendered to the Issuer in connection with the Issuer's business combination pursuant to a warrant surrender agreement, for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2021 Filed Jul 1, 2021 23:50 UTC | Ensysce Biosciences, Inc. LACQ · Entity 8108 | Disposition to issuerWarrants · Derivative | 250,000 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001493152-21-015899 · ownership.xml · derivative · entry 3 Silvers Daniel B. · CIK 0001468195 · 10% owner Matthews Lane Capital Partners LLC · CIK 0001722952 · 10% owner MLCP GLL Funding LLC · CIK 0001722935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · MLCP GLL Funding LLC Disclosed balance after: 1,754,497 Underlying: Common Stock · 250,000 shares Expires 2026-06-30 F4 · security: Reflects warrants surrendered to the Issuer in connection with the Issuer's business combination pursuant to a warrant surrender agreement, for no consideration. F4 · kind: Reflects warrants surrendered to the Issuer in connection with the Issuer's business combination pursuant to a warrant surrender agreement, for no consideration. F2 · ownership.nature: Matthews Lane Capital Partners LLC, a sponsor of the Issuer, is the manager of MLCP GLL Funding LLC, the record holder of the warrants. Mr. Silvers is the managing member of Matthews Lane Capital Partners LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 23:50 UTC | Ensysce Biosciences, Inc. LACQ · Entity 8108 | GrantWarrants · Derivative | 367,107 | $1.00 Strike: $11.50 | $367,107.00 |
DisclosureSEC source: 0001493152-21-015899 · ownership.xml · derivative · entry 2 Silvers Daniel B. · CIK 0001468195 · 10% owner Matthews Lane Capital Partners LLC · CIK 0001722952 · 10% owner MLCP GLL Funding LLC · CIK 0001722935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · MLCP GLL Funding LLC Disclosed balance after: 2,004,497 Underlying: Common Stock · 367,107 shares Expires 2026-06-30 F3 · security: Reflects warrants acquired at a price of $1.00 per warrant upon the conversion of promissory notes of the Issuer reflecting amounts loaned to the Issuer pursuant to the Issuer's expense advancement agreement, which were convertible into warrants at the holder's option. The warrants are on the same terms as the warrants described in note (1) above. F3 · kind: Reflects warrants acquired at a price of $1.00 per warrant upon the conversion of promissory notes of the Issuer reflecting amounts loaned to the Issuer pursuant to the Issuer's expense advancement agreement, which were convertible into warrants at the holder's option. The warrants are on the same terms as the warrants described in note (1) above. F2 · ownership.nature: Matthews Lane Capital Partners LLC, a sponsor of the Issuer, is the manager of MLCP GLL Funding LLC, the record holder of the warrants. Mr. Silvers is the managing member of Matthews Lane Capital Partners LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 23:50 UTC | Ensysce Biosciences, Inc. LACQ · Entity 8108 | GrantWarrants · Derivative | 1,637,390 | $1.00 Strike: $11.50 | $1,637,390.00 |
DisclosureSEC source: 0001493152-21-015899 · ownership.xml · derivative · entry 1 Silvers Daniel B. · CIK 0001468195 · 10% owner Matthews Lane Capital Partners LLC · CIK 0001722952 · 10% owner MLCP GLL Funding LLC · CIK 0001722935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · MLCP GLL Funding LLC Disclosed balance after: 1,637,390 Underlying: Common Stock · 1,637,390 shares Expires 2026-06-30 F1 · security: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Silvers served as the Issuer's Chief Executive Officer and Director until the closing of the business combination. F1 · kind: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Silvers served as the Issuer's Chief Executive Officer and Director until the closing of the business combination. F2 · ownership.nature: Matthews Lane Capital Partners LLC, a sponsor of the Issuer, is the manager of MLCP GLL Funding LLC, the record holder of the warrants. Mr. Silvers is the managing member of Matthews Lane Capital Partners LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 15, 2018 Filed Jan 17, 2018 22:18 UTC | Ensysce Biosciences, Inc. LACQ · Entity 8108 | OtherCommon Stock | 171,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-000382 · s108737_form4.xml · nonDerivative · entry 1 Silvers Daniel B. · CIK 0001468195 · Director · Chief Executive Officer Matthews Lane Capital Partners LLC · CIK 0001722952 · Sponsors of the Co. MLCP GLL Funding LLC · CIK 0001722935 · Sponsor Affiliate of the Co. Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,128,370 F1 · shares: As contemplated by the securities subscription agreement between each reporting person and the Company, 171,832 shares held by MLCP GLL Funding LLC, an affiliate of a sponsor of the Company (the "Sponsor Affiliate") and Matthews Lane Capital Partners LLC, a sponsor of the Company (the "Sponsor"), were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering. F1 · price: As contemplated by the securities subscription agreement between each reporting person and the Company, 171,832 shares held by MLCP GLL Funding LLC, an affiliate of a sponsor of the Company (the "Sponsor Affiliate") and Matthews Lane Capital Partners LLC, a sponsor of the Company (the "Sponsor"), were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering. F2 · balance_after: Represents 887,127 shares of common stock held by the Sponsor Affiliate. Represents 241,243 shares of common stock held by the Sponsor. The shares held by the Sponsor Affiliate and the Sponsor are beneficially owned by Daniel B. Silvers, who has sole voting and dispositive power over the shares held by the Sponsor Affiliate and the Sponsor. Mr. Silvers owns all of the membership interests in the Sponsor Affiliate and the Sponsor. Mr. Silvers disclaims beneficial ownership over any securities owned by the Sponsor and the Sponsor Affiliate in which he does not have any pecuniary interest. F2 · ownership.nature: Represents 887,127 shares of common stock held by the Sponsor Affiliate. Represents 241,243 shares of common stock held by the Sponsor. The shares held by the Sponsor Affiliate and the Sponsor are beneficially owned by Daniel B. Silvers, who has sole voting and dispositive power over the shares held by the Sponsor Affiliate and the Sponsor. Mr. Silvers owns all of the membership interests in the Sponsor Affiliate and the Sponsor. Mr. Silvers disclaims beneficial ownership over any securities owned by the Sponsor and the Sponsor Affiliate in which he does not have any pecuniary interest. Read SEC document |
| December 05, 2017 Filed Dec 5, 2017 23:57 UTC | Ensysce Biosciences, Inc. LACQ · Entity 8108 | OtherCommon Stock | 359,869 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-062472 · tv480824_4.xml · nonDerivative · entry 1 Silvers Daniel B. · CIK 0001468195 · Director · Chief Executive Officer Matthews Lane Capital Partners LLC · CIK 0001722952 · Sponsor of the Company MLCP GLL Funding LLC · CIK 0001722935 · Sponsor Affiliate of the Co. Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,300,202 F1 · shares: As contemplated by the securities subscription agreement between each reporting person and the Company, 359,869 shares held by MLCP GLL Funding LLC, an affiliate of a sponsor of the Company (the "Sponsor Affiliate") and Matthews Lane Capital Partners LLC, a sponsor of the Company (the "Sponsor"), were forfeited upon consummation of the Company's initial public offering for no consideration. F1 · price: As contemplated by the securities subscription agreement between each reporting person and the Company, 359,869 shares held by MLCP GLL Funding LLC, an affiliate of a sponsor of the Company (the "Sponsor Affiliate") and Matthews Lane Capital Partners LLC, a sponsor of the Company (the "Sponsor"), were forfeited upon consummation of the Company's initial public offering for no consideration. F2 · balance_after: Includes an aggregate of 171,833 shares held by the Sponsor Affiliate and the Sponsor that are subject to forfeiture to the extent that the underwriters' overallotment in the Company's initial public offering is not fully exercised. F3 · ownership.nature: Represents 1,022,222 shares of common stock held by the Sponsor Affiliate. Represents 277,980 shares of common stock held by the Sponsor. The shares held by the Sponsor Affiliate and the Sponsor are beneficially owned by Daniel B. Silvers, who has sole voting and dispositive power over the shares held by the Sponsor Affiliate and the Sponsor. Mr. Silvers owns all of the membership interests in the Sponsor Affiliate and the Sponsor. Mr. Silvers disclaims beneficial ownership over any securities owned by the Sponsor and the Sponsor Affiliate in which he does not have any pecuniary interest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.